Author： Tyrka Audrey R. Price Lawrence H. Mello Marcelo F. Mello Andrea F. Carpenter Linda L.
Publisher： Adis International
ISSN： 0114-5916
Source： Drug Safety, Vol.29, Iss.6, 2006-01, pp. : 491-508
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
A Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression
Drug Safety, Vol. 34, Iss. 9, 2011-09 ,pp. :
Access to resources
Recommend
Benefit-Risk Assessment of Bevacizumab in the Treatment of Breast Cancer
Drug Safety, Vol. 35, Iss. 1, 2012-01 ,pp. :
Benefit-Risk Assessment of Levetiracetam in the Treatment of Partial Seizures
Drug Safety, Vol. 28, Iss. 10, 2005-01 ,pp. :
Benefit-Risk Assessment of Infliximab in the Treatment of Rheumatoid Arthritis
By Mikuls T.R.
Drug Safety, Vol. 26, Iss. 1, 2003-01 ,pp. :
Benefit-Risk Assessment of Rofecoxib in the Treatment of Osteoarthritis
By Schmidt H. Woodcock B.G. Geisslinger G.
Drug Safety, Vol. 27, Iss. 3, 2004-01 ,pp. :